NICE Opposes Ponvory Being Added to NHS for England and Wales

NICE Opposes Ponvory Being Added to NHS for England and Wales

308799

NICE Opposes Ponvory Being Added to NHS for England and Wales

The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be sufficiently cost effective, means that the oral therapy will not be available at low or no cost to patients with clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS…

You must be logged in to read/download the full post.